Daily Chart: TIGIT pipeline heats up

With last week’s data from Genentech, the next-generation checkpoint target TIGIT has started to out-shine its peers. At least 11 TIGIT inhibitors are coming up behind Genentech’s tiragolumab in the pipeline.

The Roche unit released Phase II data ahead of ASCO demonstrating an added clinical benefit when tiragolumab was combined with Tecentriq atezolizumab in PD-L1-positive metastatic non-small cell lung cancer (NSCLC), making TIGIT the first next-generation checkpoint to produce positive results in a randomized controlled Phase II trial (see “TIGIT Breaks Through as Next-Generation Checkpoint Target”). ...